Andrew Obenshain

Salesforce Amazon SES Mailchimp Mandrill Rackspace MailGun Sendgrid Mimecast Outlook Microsoft Office 365 Microsoft Azure Hosting Drupal Atlassian Cloud Leadfeeder Greenhouse.io Mobile Friendly New Relic Google Tag Manager Bing Ads MouseFlow Google Analytics Remote

gene therapy gene addition sickle cell disease betathalassemia cerebral adrenoleukodystrophy biotechnology life sciences biotechnology: biological products (no diagnostic substances) health care biotechnology research curative therapies lentiviral vector ex-vivo gene therapy one-time treatments beta-thalassemia hemoglobinopathies patient advocacy clinical trials genetic diseases healthcare access blood transfusions iron overload hospital visits disease management chronic conditions genome editing therapeutic potential disease modification clinical research approvals fda-approved therapies patient resources biotech innovation manufacturing sciences quality assurance therapeutic advancements access policies collaborations biopharmaceuticals regulatory compliance medical education transfusion-dependent thalassemia diagnostic testing patient outcomes treatment options research development translational medicine genetic screening comprehensive care medical ethics community engagement clinical practice disease burden biotech partnerships diversity & inclusion corporate giving severe genetic diseases cancer immunotherapy lentiviral vector technology personalized treatment transfusion-dependent beta thalassemia innovative therapies patient-centric care curative treatments rare genetic disorders patient support services research & data leadership inclusivity healthcare equity collaboration innovation integrity excellence transformative healthcare genetic disorders advanced therapies patient well-being genetic causes proprietary technology clinical development patient journey healthcare solutions market focus therapeutic pipeline patient demographics healthcare innovation health wellness & fitness hospital & health care